Business Opportunities

Intas Pharma ties up with US company

Ahmedabad-based Intas Pharmaceuticals Ltd (Intas) has entered into a strategic partnership with US biotechnology company Amarillo Biosciences, Inc (ABI), whereby Intas will sponsor clinical trials of ABI’s orally administered interferon-alpha lozenges for influenza, which could also be used in combating the H1N1 virus. Sensex ends up 35pts According to recent reports, the death rate in India from H1N1 infection is 3.1 per cent and the virus continues to circulate in the country.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

Categories
Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business
News of the day
Aditya Birla PE Fund to pick up 0.5% in BSE
Aditya Birla Private Equity Fund, which is looking to raise Rs 1,250 crore, has finalised some investments, including 0.5 per cent in the country’s oldest exchange, the Bombay Stock Exchange, said sources close to the development.
Popular Articles
payday loans no faxing

Sunil Jain: Golden and other rules
- RIL gas production cost comparable with others: DGH - Move Mr Deora - RNRL wants CAG audit of RIL gas fields made public - Anil blames Mukesh for delay in Dadri power plant - Govt files fresh plea on Ambani gas dispute - SC rejects RNRL plea for final hearing of gas row on Sept 1

The economics of caste inequity
Reactions to the caste question are fairly predictable in India. The average (upper caste) response is that the policy of reservations has gone on far too long and that discrimination is very much a thing of the past. As to why certain social groups remain extremely poor and backward despite the legal safeguards, the usual explanation is that Dalits are either not well educated or do not have the merit to make it to good jobs.

© Copyright 2009